U.S. seeks to 'onshore' drug production in response to COVID-19. Is pharma even interested?

With the COVID-19 pandemic shining a spotlight on the global pharmaceutical supply chain, U.S. legislators have put forward a raft of legislation that would seek to "onshore" drug manufacturing at the expense of major producers abroad, particularly China.

Guess who's wary of that proposal? Big Pharma.